Batm Advanced Communicat... Share Discussion Threads

[madun2000] 03/2/2022 09:09

Don't panic. Removing from the index doesn't mean every fund has to sell. Only those that are explicit index trackers. Lots of active funds have the ability to own off index stocks and, indeed, unlisted companies. This announcement is noise.

The positives are:

1)company announcing a 10% share buyback. highlights confidence is business outlook and strong cash position. wouldn't be doing this if they thought cashflow was going to be tough.

2) for those that want a US listing... this has to be a reason to switch index...

[nellyb] 03/2/2022 08:59

carpet, yes i think you sold out ages ago so well done you.

[nellyb] 03/2/2022 08:54

sandy - no. funds that follow the FTSE UK Index Series will have to sell/reallocate bvc.

[car1pet] 03/2/2022 08:49

Well the share price is now 55p investors are getting out. Which bit of incompetence needs clarifying. He didn't understand the position in the FTSE was at risk. I've been saying it for years. He is not a CEO. This is proof. He makes Boris Johnson look smart.
Those investors who bought above £1 must be angry.

[sandy789] 03/2/2022 08:46

I hold in SIPP and also an ISA will those have to be sold ???

[nellyb] 03/2/2022 08:27

carpet, sorry, in what way?

[car1pet] 03/2/2022 08:24

More incompetence by Marom.

[paulisi] 03/2/2022 08:16

Removed from UK index series - so any funds holding will have to sell.However the share buyback should compensate. The company are clearly swimming in cash with the 4m in Ador, the buyback and the dividend payout. Still not spent the money from the sale of NG Soft.

[wizzkid211] 03/2/2022 07:01

BATM Advanced Communications Ld Update on FTSE Nationality Review & Share Buyback
03/02/2022 6:59am
UK Regulatory (RNS & others)

Batm Advanced Communicat... (LSE:BVC)
Intraday Stock Chart

Thursday 3 February 2022

Click Here for more Batm Advanced Communicat... Charts.
TIDMBVC

RNS Number : 5381A

BATM Advanced Communications Ld

03 February 2022

LEI: 213800FLQUB9J289RU66

3 February 2022

BATM Advanced Communications Limited

("BATM" or "the Group")

Update on FTSE Nationality Review

and Share Buyback Programme

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, notes that in the FTSE Nationality Review of Companies published by FTSE Russell on Wednesday 2 February 2022, the Group's nationality has been reassigned from the UK to Israel. The Group also announces its intention to launch a share buyback programme, subject to the receipt of shareholder approval.

FTSE Nationality Review

As stated in the announcement of 17 January 2022, BATM remains committed to maintaining its membership of the FTSE UK Index Series (the "Index") and remains in dialogue with FTSE Russell to investigate possibilities of an extension. Should an extension not be granted, the reassignment of BATM's nationality will take effect from 21 March 2022, pursuant to rule 5.1.6 of the Ground Rules of the Index.

Zvi Marom, Chief Executive Officer of BATM, said: "We are very disappointed by the decision of FTSE Russell not to grant us a further extension and maintain our membership of the FTSE UK Index Series. We are puzzled by this decision as we have been in regular dialogue with them and had certain indications that it would be granted.

"We are not the only company that has been denied this by virtue of our domicile and dual listing. A lack of pragmatism and blindness to the possibility of market disruption is fast becoming a deterrence for good foreign-domiciled companies to list on the London Stock Exchange, especially when other bourses do not have such draconian rules. We hope the lawmakers look at this again and become welcoming to global companies who wish to give investors in index-linked funds in the UK as well as those in their own countries the opportunity to invest in them."

Share Buyback Programme

The Board of BATM has approved a share buyback programme of ordinary shares of NIS0.01 in the capital of the Group of up to 10% of the Group's issued share capital (the "Buyback Programme"). The Group has a strong balance sheet and the Buyback Programme, which would be funded from the Group's net cash position, forms part of the Board's broader strategy to deliver shareholder value. The commencement of the Buyback Programme is subject to the approval of shareholders at a general meeting to be convened. F urther details on the Buyback Programme will be provided in the notice of general meeting and the Group will update the market in due course.

Enquiries:

[paulisi] 31/1/2022 18:26

Prior to the interview I got the impression the May launch would be the start of the commercial revenue stream.Listening to the interview, some sales in Q3, but lots of proof of concept required and serious money not for another few years.This should be a game changer and if the theory is correct every hospital should purchase as a replacement for a standard PCR test

[fse] 31/1/2022 15:20

This is all far further ahead than most people realised and we are going to see a large "reveal" in May where they will unveil the system.
Its hard to quantify just what this means to the field of molecular diagnostics, this is the next "future" platform and its not hard to see the advantages.
The ability to test simultaneously and rapidly not just for multiple pathogens but also provide matching treatment protocols is a complete game changer.
They could easily raise whatever they want at this stage of the development where they have proven concepts and hardware to run it on but the good news for us shareholders "again" is that they are not diluting the company by going outside for funds.
There are elements in this that are being developed that would not be so easy for even a large multinational. By this I mean (amongst others) the AI ability to match treatments with test results.
This will not only provide a more direct, faster and specific treatment but save the medical profession untold amounts of time and money in correct diagnosis.
This is a win win concept/solution as doctors/hospitals time and funds are stretched to the limit.

The uniqueness of this system evolves around the ability to multi test and match results to treatments. A lot of the patents appear to be centerer around this area.
This is a $bn + piece of IP too bad the market can not see it but its going to shortly get a lot of attention.

[wizzkid211] 31/1/2022 09:48

PAULISI
All that is done in-house without going to the market for more dosh

[paulisi] 31/1/2022 09:29

Effectively added $4m for 0.5%This values Ador share at $150m.If you add on the other divisions - Telco, Eco Med, Cyber etc then the valuation far underway the stock market valuation.

[wizzkid211] 31/1/2022 07:01

BATM Advanced Communications Ld Update on Ador Diagnostics
31/01/2022 6:59am
UK Regulatory (RNS & others)

Batm Advanced Communicat... (LSE:BVC)
Intraday Stock Chart

Monday 31 January 2022

Click Here for more Batm Advanced Communicat... Charts.
TIDMBVC

RNS Number : 0598A

BATM Advanced Communications Ld

31 January 2022

LEI: 213800FLQUB9J289RU66

31 January 2022

BATM Advanced Communications Limited

("BATM" or "the Group")

Update on Ador Diagnostics

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, is pleased to provide an update on progress with its associate company, Ador Diagnostics Ltd ("Ador"), and BATM's participation in a $10m follow-on investment into Ador.

Ador is developing the advanced NATlab molecular biology solution that provides rapid sample-to-answer isothermal diagnosis of bacterial, viral or fungal infections using DNA or RNA sampling. Diagnostic molecular biology is the fastest growing area of laboratory medicine, and the Directors believe that it has the potential to have a major impact on the way infectious disease diagnosis and fast treatment is initiated.

Ador progress in the past 12 months

-- Successful completion of clinical trial of meningitis diagnostics panel;
-- Development of the RCA (isothermal) protocol, which has been finalised and tested resulting in biology R&D risk being reduced to a minimum;

-- Patents have continued to be submitted in the United States; and
-- Alongside BATM's Adaltis subsidiary, Ador entered into a partnership with the Stop TB Partnership, Heidelberg University and the "Find" programme. Products under this programme are going through the testing phase and the Group expects substantial-scale commercial testing next year.

Investment into Ador

Further to the announcement of 15 December 2020, the Group and its partners in Ador have invested an additional amount of $10m, of which the Group has contributed $4m. Following this additional investment, the Group's shareholding in Ador will be 37.21% (compared with 36.7% in December 2020).

The additional investment will be used to prepare Ador for the pre-production stage, register additional patents (mainly in the USA), progress development of more disease panels and certifications, and increase the co-operation with international bodies including the WHO.

Dr Zvi Marom, CEO of BATM, said: "We are pleased at the progress Ador is making. I am confident that we are paving a new path to diagnose infectious diseases. This investment will enable us to prepare Ador for the pre-production stage and move it towards becoming a commercial clinical solution.

"The pandemic has demonstrated that viral, microbial or pathogenic diseases continue to be a very real threat to all aspects of our life. There is a great need to gain a better understanding of how structural variations in DNA and RNA are associated with the development of infectious diseases, whether acute or chronic, and to develop fast diagnostics that can be operational at both the point of care and in labs that enable appropriate and immediate treatment. We look forward to the next phase of development in Ador."

Enquiries:

[rawdeal1] 29/1/2022 12:20

"Agility is booming and if Vodafone sign up" ..... I suppose the obvious question is why haven't Vodafone signed up. They've done the trials and it does work .... but yet we haven't heard from them since the successful POC in Aug 2020.
With the roll out of 5 G etc ... one would have thought they would be using their technology by now.

[fse] 28/1/2022 19:01

Some weekend reading on Rolling Circle Amplification and what Ador Diagnostics is involved with.
It is presumed that RCA will replace PCR as the new gold standard.
From my understanding Ador have got this to work with a NatLab reader and are close to producing a saleable solution.

[paulisi] 28/1/2022 17:53

Podcast is very interesting - need to listen again, but lots of new information.Spin off could generate hundreds of millions of revenue.Agility is booming and if Vodafone sign up, it could be worth 15-20 million in profit per year and growing.Eco-med could be the secret growth area.Definitely undervalued and if you are prepared to sit and wait, you should be quids in, both via share price growth and dividend growth/special dividends

[latifs100] 28/1/2022 16:28

any ideas on cash and debt levels, holding from 145

[cumnor] 27/1/2022 21:55

Many thanks FSE. Zvi as entertaining as ever and the timing certainly suggests the market is completely off in valuation. Agree and may buy more if it drops further-although I have loads as it is.

[unctuous] 27/1/2022 18:59

FSE - that is a great podcast! Thanks for bringing it to our attention.

[james dean] 27/1/2022 18:51

Hi TC

HNY

I have topped up also a little earlier than yourself.

[deeker] 27/1/2022 18:45

On a quick look at chart there doesn't seem to be much to stop this heading back to pre pandemic 40/50 range

[the crypt] 27/1/2022 16:50

The Crypt has been holding forever and topped up today - adding another 2,000 shares. This is definitely a buying opportunity.